This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Latest news, analysis and insight in fastest growing sector in agriculture.

KitoZyme’s KitoGreen obtains EC approval

Share this article

KitoZyme, manufacturer of fungal chitosan, has been granted approval for its KitoGreen products by the European Commission as Basic Substances for Plant Protection, for multiple applications and crops.

The company announced in March that it had obtained U.S. Environmental Protection Agency (EPA) approval, and was working on some state-level approvals.

KitoGreen was developed by KitoZyme to offer more sustainable options for farmers who are looking for greener elicitor, antibacterial and antifungal products. KitoGreen is patented and it is based on the valorization of co-products of the food industry. Being primarily sold as an ingredient for food but also as an ingredient for cosmetics and as processing aid for winemaking, KitoGreen was eligible to a status of Basic Substance in the European Union.

KitoGreen is derived from Aspergillus niger, and the company had already proven the efficacy of its compound for the prevention and the treatment of fungal diseases on a wide variety of crops, including vegetables, grapes, berries and sports turfs.

According to Guillaume Deleixhe, business development manager, the company is continuously strengthening its scientific knowledge and will “further advance the science of KitoGreen, either on a stand-alone basis or in partnerships with our customers. Besides foliar applications, we already have good data for seed treatment, and we are aware that it could also be a very good fit post-harvest.”

The Belgium-based company is working on commercial partnerships to make the product available in the coming weeks for all users across Europe.

Subscribe to 2BMonthly for regular updates on regulatory issues regarding biological products, here. An interview with KitoZyme is scheduled for the May 2022 issue.

Share this article